文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

载 ROR1siRNA 的靶向递药 theranostic 丝胶/SPION 纳米粒:合成、表征、诊断及对三阴性乳腺癌的抗癌作用。

Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer.

机构信息

Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.

Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Int J Biol Macromol. 2022 Nov 30;221:604-612. doi: 10.1016/j.ijbiomac.2022.09.020. Epub 2022 Sep 7.


DOI:10.1016/j.ijbiomac.2022.09.020
PMID:36084874
Abstract

Triple-negative breast cancer (TNBC) has the worst prognosis among all breast cancer subtypes. The lack of proper treatments prompted scientists to find a practical targeted therapy to treat this type of tumor. Based on previous studies, tyrosine kinase-like orphan receptor (ROR1) is overexpressed in TNBC cells. Here, we designed a system consisting of superparamagnetic iron oxide nanoparticles (SPIONs) decorated with silk sericin (SS NPs) for the targeted delivery of ROR1 siRNA, a gene silencer to knockdown the expression of human ROR1 gene. NPs exhibited spherical shape of about 193 nm with acceptable properties both in vitro and in vivo. The apoptosis study showed significant death of MDA-MB-231 cells after 24 h treatment with the prepared NPs. The real-time PCR study also demonstrated an almost complete shutdown of ROR1 expression. Guided by magnetic field, enhanced accumulation of NPs was observed in breast tumors induced by 4T1 cells in BALB/c mice. Histological evaluation of the tumor exhibited necrosis 14 days post-treatment with the siRNA-loaded NPs; whereas, the untreated tumor was proliferating. Also, the tumor growth rate was significantly decreased after treatment with siRNA-loaded NPs in vivo. In conclusion, the prepared delivery system could be considered as a potential therapeutic strategy for treating TNBC.

摘要

三阴性乳腺癌(TNBC)是所有乳腺癌亚型中预后最差的。由于缺乏适当的治疗方法,科学家们正在寻找一种实用的靶向治疗方法来治疗这种肿瘤。基于之前的研究,酪氨酸激酶样孤儿受体(ROR1)在 TNBC 细胞中过表达。在这里,我们设计了一个由超顺磁性氧化铁纳米粒子(SPIONs)修饰丝胶(SS NPs)组成的系统,用于靶向递送 ROR1 siRNA,这是一种基因沉默物,可降低人 ROR1 基因的表达。NPs 呈球形,约 193nm,具有可接受的体外和体内性能。凋亡研究表明,用制备的 NPs 处理 MDA-MB-231 细胞 24 小时后,细胞死亡显著。实时 PCR 研究还表明 ROR1 表达几乎完全关闭。在 BALB/c 小鼠中,由 4T1 细胞诱导的乳腺癌中,磁场引导下观察到 NPs 的增强积累。治疗 14 天后,用负载 siRNA 的 NPs 处理的肿瘤表现出坏死;而未经处理的肿瘤则在增殖。此外,体内用负载 siRNA 的 NPs 治疗后,肿瘤生长速度显著降低。总之,所制备的递药系统可被视为治疗 TNBC 的一种潜在治疗策略。

相似文献

[1]
Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer.

Int J Biol Macromol. 2022-11-30

[2]
Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.

PLoS One. 2019-5-31

[3]
Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modified Redox Responsive PEG-PEI Nanoparticles for the Treatment of Triple-Negative Breast Cancer.

Mol Pharm. 2021-11-1

[4]
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.

Breast Cancer Res. 2022-6-3

[5]
miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.

Oncol Rep. 2018-4-18

[6]
Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.

BMC Cancer. 2023-11-27

[7]
β-.

J Immunother Cancer. 2020-4

[8]
Expression of ROR1 has prognostic significance in triple negative breast cancer.

Virchows Arch. 2016-5

[9]
Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.

Drug Deliv. 2017-11

[10]
Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.

Mol Pharm. 2018-3-12

引用本文的文献

[1]
Recent Insights into the Potential and Challenges of Sericin as a Drug Delivery Platform for Multiple Biomedical Applications.

Pharmaceutics. 2025-5-26

[2]
Compliant immune response of silk-based biomaterials broadens application in wound treatment.

Front Pharmacol. 2025-2-12

[3]
Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery.

Int J Nanomedicine. 2024

[4]
SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer.

Biomed Microdevices. 2024-2-7

[5]
Visualization of breast cancer-related protein synthesis from the perspective of bibliometric analysis.

Eur J Med Res. 2023-10-27

[6]
A Recent Review on Cancer Nanomedicine.

Cancers (Basel). 2023-4-12

[7]
Protein-Caged Nanoparticles: A Promising Nanomedicine Against Cancer.

Chonnam Med J. 2023-1

[8]
Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1.

Biomedicines. 2022-10-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索